Article

First patient dosed in QLT trial

QLT Inc. has announced that the first patient in the company’s phase IIa proof-of-concept trial of QLT091001 in adult subjects with impaired dark adaption (IDA) has been dosed.

 

Vancouver, British Columbia-QLT Inc. has announced that the first patient in the company’s phase IIa proof-of-concept trial of QLT091001 in adult subjects with impaired dark adaptation (IDA) has been dosed.

The trial is a randomized, multicenter, parallel-group, placebo-controlled study.

Patients (age 60 or older) with IDA or impaired low luminance low contrast best-corrected visual acuity (LLLC BCVA) in at least one eye and who have no known ophthalmic pathologies to explain their condition-other than early age-related macular degeneration-will be enrolled at sites in the United States.

Patients will be randomly assigned to receive the placebo or one of two different doses (10 or 40 mg/m2) of the drug once per week for 3 consecutive weeks with one additional dose the day after the third dose.

The trial is designed to evaluate the safety profile and effects of the drug on IDA time, glare recovery time, and LLLC BCVA.

“We are pleased that dosing of the first patient has occurred on schedule, marking another significant milestone for QLT in the advancement of our synthetic oral retinoid program in multiple indications,” said Jason M. Aryeh, board chairman of QLT. “This is an important step outside of rare orphan diseases with (the drug), one which is designed to illustrate its potential in a significantly larder patient population.”

 

For more articles in this issue of Ophthalmology Times eReport, click here.

 

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.